Increase of authorized share capital

Leiden, The Netherlands, October 1, 2010.  Biotech company Pharming Group NV
("Pharming" or "the Company") (NYSE Euronext: PHARM) announced today the
appointment of Dr Karl Keegan as Chief Financial Officer (CFO) effective today
and the increase of its authorized share capital to 500 million shares. These
decisions were taken by the Shareholders at an Extraordinary Meeting (EGM) held
today.

The Shareholders have approved the proposal to appoint Dr Karl Keegan as CFO and
member of the Board of Management of Pharming with effect October 1, 2010. Dr
Keegan will be responsible for all financial and financing activities, corporate
communications and investor relations. In addition, Dr Keegan will work closely
together with Dr de Vries in furthering the Company´s business development
activities. In addition, Pharming requested and received approval from its
Shareholders to increase the authorized number of shares from 400 million to
500 million. Prior to today´s EGM, Pharming´s number of outstanding shares,
available for issuance, was confined to a little over 40 million. The
possibility to, if necessary, issue additional shares, provides for sufficient
share capital to secure Pharming´s financial position

Dr Sijmen de Vries, Chief Executive Officer of Pharming: "We would like to
welcome Karl to the Board of Management and look forward to working together on
the strengthening of our relationships with current and potential shareholders
and building financial stability for Pharming."

Mr Jaap Blaak, Chairman of Pharming´s Board of Supervisory Directors, said:
"With the appointment of Karl as Chief Financial Officer, we consider the Board
of Management is now at optimum strength and ready to resolve the last financial
challenges. The increased authorized share capital will facilitate the Company
achieving financial stability, securing the Company´s future and creating
long-term value for its Shareholders."